Search page

ANCHOR-1 and 2 Study Design: Replicate Phase 3 Randomised, Double-Blind, Placebo-Controlled Studies of the Efficacy and Safety of Depemokimab in Patients with Chronic Rhinosinusitis with Nasal Polyps

An interim analysis of a multi-center, oPEn label, Randomized study to investigate the saFEty of an optimal acCelerated scheme for immunoTherapy in adolescent and adult patients with moderate to severe AR with or without asthma in China. (PERFECT)

Assessing the long-term effectiveness and safety of LTP in HAE

Assessment of the safety of allogenic natural killer cells in the treatment of metastatic colon cancer

Biologics for allergic diseases: efficacy and safety in a pediatric population of a tertiary hospital center

Blinded Safety Outcomes Of The COMBINE Study

Bumblebee venom allergy as an emerging occupational allergy: safety and efficacy of bumblebee venom immunotherapy in a large single-center cohort

CHAPTER-3 Phase 3 Trial Design: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks

Challenging decisions: Feasibility and safety of multiple low-risk drug challenges in a single clinic visit during peri-operative anaphylaxis investigation

Clinical significance and safety of provocation test for drug allergy diagnosis in outpatient unit: A real world observational study

Codex Alimentarius & Precautionary Allergen Labelling (PAL): A New Era for Food Safety and Patient Information

Comparative Efficacy and Safety of Omalizumab Intended copy Biosimilar vs. Biologic in Chronic Spontaneous Urticaria

Definition of sensitization to risk molecules of systemic reactions in patients with food allergies and the significance of product labeling for their safety

Design of a phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of tezepelumab in adult patients with severe chronic rhinosinusitis with nasal polyposis (WAYPOINT)

EFFECTIVENESS AND SAFETY OF SPECIFIC SUBLINGUAL IMMUNOTHERAPY WITH Pru p3 EXTRACT IN PATIENTS WITH LTP ALLERGY

Effectiveness and Safety Study of Subcutaneous Immunotherapy for Respiratory Allergy to Dermatophagoides and Lepidoglyphus Destructor

Effectiveness and Safety of Dupilumab in patients with chronic rhinosinusitis with nasal polyps After One Year of Therapy: Results from a real-world non-interventional study in Germany (ProGNOSE)

Effectiveness and safety of Venom ImmunoTherapy (VIT) with “Rapid Cluster” induction protocol

Effectiveness and safety of berotralstat in patients with hereditary angioedema with normal C1-inhibitor: A European case series

Efficacy and safety of tezepelumab in adults with severe chronic rhinosinusitis with nasal polyps overall and in patients with and without co-morbid asthma: results from the phase 3 WAYPOINT study

Efficacy and Safety Analysis of Omalizumab in Treating Wheat-Dependent Exercise-Induced Anaphylaxis (WDEIA) in the Chinese Population

Efficacy and Safety of 1-Year Dupilumab Treatment in Children Aged 6-11 years with Moderate-to-Severe Atopic Dermatitis in South Korea: Multicenter Prospective Observational Study

Efficacy and Safety of Chemotherapeutic Drug Desensitization in Children

Efficacy and Safety of Donidalorsen for Hereditary Angioedema Among Patients in Europe: A Regional Subanalysis of the Phase 3 OASIS-HAE Study

Efficacy and Safety of Dupilumab Treatment for Adult Allergic Bronchopulmonary Aspergillosis (ABPA): A Real-World Analysis of 16 Cases in China

Efficacy and Safety of Dupilumab in Children Aged 6 Months to 5 Years With Atopic Dermatitis With and Without Type 2 Comorbidities

Efficacy and Safety of Hymenoptera Venom Immunotherapy

Efficacy and Safety of Omalizumab in Treating Severe Allergic Reactions with Urticaria as the Initial Symptom

Efficacy and Safety of Oral Deucrictibant, a Potent Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial

Efficacy and Safety of the 4-Step Egg and 5-Step Cow’s Milk Ladders in a High Risk Group of Children with IgE-mediated Food Allergy: A Case Series

Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks: RAPIDe-3 Phase 3 Trial Design

Efficacy and safety of ALK 300 SRU 5-grass mix SLIT-drops in adults with grass pollen-induced rhinoconjunctivitis: results of the phase III trial RHAPSODY

Efficacy and safety of HDM-specific subcutaneous immunotherapy on atopic dermatitis

Efficacy and safety of Mepolizumab in treatment of eosinophilic granulomatosis with polyangiitis

Efficacy and safety of Omalizumab in a Patient, previously undergoing liver transplantation, with facial angioedema, unresponsive to corticosteroids and antihistamines

Efficacy and safety of allergen immunotherapy in clinical practice

Efficacy and safety of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis (AD): a phase 2b trial (STREAM-AD)

Efficacy and safety of biologics in children for food allergy

Efficacy and safety of dupilumab versus omalizumab in patients with severe chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST): Results from a prospective, head-to-head phase 4 trial

Efficacy and safety of sublingual immunotherapy for mite in children and adolescents with AR

Efficacy and safety of switching to bilastine, a histamine H1 receptor antagonist, in patients with refractory chronic spontaneous urticaria (H1-SWITCH): a phase IV, multicenter, open-label, randomized, parallel-group comparative controlled trial

Efficacy and safety of therapy with omalizumab in children with chronic spontaneous urticaria

Evaluation of Early Real-World Efficacy and Safety of Mepolizumab in Chronic Rhinosinusitis with Nasal Polyposis Through a Multidisciplinary Approach

Evaluation of the Safety of Mixed Tree Nut Oral Food Challenges in the Management of Tree Nut Allergy

Exposure-adjusted safety of peanut (Arachis hypogaea) allergen powder-dnfp oral immunotherapy in individuals with peanut allergy aged 1-3 years (POSEIDON trial)

Fixed-Dose Oral Immunotherapy for High-Threshold Food Allergy: Efficacy and Safety in Real-World Practice

Head-to-head comparison between allergist vs. non-allergist in low risk penicillin allergy delabelling: effectiveness, safety and impact on quality of life from a multi-centre, prospective cohort study in Hong Kong (HK-DADI2)

Hereditary angioedema prophylaxis therapy: berotralstat and lanadelumab safety profile

High degree of sustained unresponsiveness and safety after three years of slow up-dose peanut oral immunotherapy in toddlers – results from the SmaChO study (Small Children Oral Immunotherapy)

Hypersensitivity reactions associated with the use of food supplements containing propolis. Analysis of observations reported to the French National Agency for Food, Environmental and Occupational Health Safety (Anses)

Immunologic profile and safety of milk oral immunotherapy in children with severe cow’s milk allergy – a series of cases

Immunotherapy with Vespa velutina nigrithorax venom: safety of ultra-rush protocol and preliminary clinical results

In vitro and ex vivo assessment of the immunogenicity and safety of a depigmented-polymerized extract from Juniperus ashei

In vitro safety profile and tolerogenic response with depigmented and polymerized extracts in polyallergic patients to grass pollen and cat epithelia

In vitro sensitisation assay for safety assessment of alternative proteins

Integrated Safety Analysis of Abrocitinib in 3848 Patients With Moderate-To-Severe Atopic Dermatitis: Data From More Than 7000 Patient-Years With Up to 4.5 Years of Exposure

Exploratory Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of YH35324, a Long-Acting high-affinity IgETrap-Fc protein, in Patients with Chronic Spontaneous Urticaria Refractory to Omalizumab

Interim safety review of PVX108 peptide immunotherapy in an ongoing Phase 2 trial in peanut-allergic adolescents and children

International Eczema Council symposium : Safety of JAK inhibitors in the treatment of inflammatory skin diseases

Joenja efficacy and safety data

Lanadelumab safety and efficacy in patients aged ≥12 with hereditary angioedema (HAE) in China for long-term prophylaxis (LTP): An open-label, multicenter study

Long term laboratory safety of dupilumab in patients aged 6 months to 5 years with moderate-to-severe atopic dermatitis

Long-Term Efficacy and Safety of Remibrutinib in Patients with Chronic Spontaneous Urticaria in the Phase 3 REMIX-1 and REMIX-2 Studies

Long-Term Efficacy and Safety of Stapokibart in Patients with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Pivotal Phase 3 Trial

Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Data Snapshot Results of the CHAPTER-1 Open-Label Extension Study

Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study

Long-term safety and efficacy of navenibart in participants with hereditary angioedema (HAE): Initial combined results from ALPHA-STAR and ALPHA-SOLAR

Long-term safety of donidalorsen for the treatment of hereditary angioedema: Results from the phase 3 open-label extension OASISplus study

Long-term safety of garadacimab in patients with hereditary angioedema from the Phase 3 open-label extension study: an up to 3-year interim analysis

Mepolizumab’s Safety and Efficacy in Children and Adolescents with Severe Eosinophilic Asthma: A Real-World Perspective

Nanoparticles to improve safety and efficacy of allergen specific immunotherapy: comparison of mesoporous silica nanoparticles and cubosomes

Navigating Oral Food and Drug Provocation Tests: Assessing Tolerance and Safety in Clinical Settings

Pediatric and Adult Responses to Fourth-Fold Antihistamine Doses: Insights into Efficacy and Safety

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Stapokibart in Healthy and Atopic Dermatitis Adult Subjects

Phase 2 Study to Evaluate the Sensitivity, Specificity, and Safety of DBV1605 as a Diagnostic Tool for Non–IgE-Mediated Cow’s Milk Allergy in Children (APTITUDE)

Primary and Safety Outcomes of a Phase 3, Open-Label, Single-Arm, 12-Week Study of Treatment with PI3Kδ Inhibitor Leniolisib in Paediatric Patients Aged 4–11 Years With Activated PI3Kδ Syndrome (APDS)

ROAD Study: Long-term Efficacy and Safety of Topical Therapy in Pediatric Moderate to Severe Atopic Dermatitis

Real life effectiveness and safety of sublingual immunotherapy with aeroallergens. A retrospective study

Real-World Effectiveness and Safety of Lanadelumab for Hereditary Angioedema Attack Prophylaxis: A 3-Year Interim Analysis of the ENABLE Study

Real-life Non-interventional Post authorization Safety Study with the SQ tree sublingual immunotherapy tablet

Real-life experience and the safety of Immunobiologicals in the treatment of immunoallergic diseases

Real-life use of biologicals in CRSwNP: prescription patterns, safety and prediction of response

Real-world evidence study on the effectiveness and safety of lanadelumab in France: the SERENITI study

Real-world study: safety and effectiveness of a subcutaneous glutaraldehyde, polymerized undiluted D.pteronyssinus-D.farinae allergen extract

Real-world study: safety and effectiveness of a subcutaneous glutaraldehyde, polymerized undiluted olive-grasses allergen extract

SCHOOL ALERT: Ensuring Safety for Students with Severe Allergies

Safety And Efficacy Of Food Ladders In Infants Presenting With Anaphylaxis

Safety Data for House Dust Mite and Pollen Subcutaneous Allergen Immunotherapy in Children: Systemic Reactions and Risk Factors

Safety Profile and Clinical Outcome of Sublingual Immunotherapy (SLIT) with Pru p 3 in Patients with LTP Allergy Undergoing Food Reintroduction

Safety and Efficacy of Oral Deucrictibant for Treatment of Upper Airway and Laryngeal Hereditary Angioedema Attacks: Results from the RAPIDe-2 Extension Study

Safety and Efficacy of VIT against Wasp Venom in Patients Older than 60 Years

Safety and Efficacy of Vancomycin and Other Antimicrobial Drug Desensitization in Pediatric Patients

Safety and Tolerability of Rush Updosing Using a Mugwort Allergoid Extract for Subcutaneous Allergen Immunotherapy

Safety and compliance of sublingual immunotherapy with house dust mite extract in patients with atopic dermatitis for 1 year

Safety and effectiveness of Jorveza® in 9 children with eosinophilic esophagitis (EoE)

Safety and effectiveness of Omalizumab for Cold Urticaria in pediatric age

Safety and efficacy of a 7-week immunotherapy protocol with aluminum hydroxide adsorbed bee venom

Safety and efficacy of dietary advancement therapies: a systematic review and meta-analysis

Safety and feasibility of very low dose challenge for children with egg allergies

Safety and tolerability of in-season initiation of subcutaneous and sublingual allergen immunotherapy with SQ grass pollen products: a comprehensive review

Safety and tolerability of ultra-rush induction protocols with Hymenoptera venoms using depot extracts

Safety and tolerance response of a two day rush protocol treatment in immunotherapy using purified Apis mellifera dry Honeybee venom extract

Safety assessment of garadacimab in clinical studies involving patients with hereditary angioedema, idiopathic pulmonary fibrosis, and COVID-19

Safety data of subcutaneous inmunotherapy at an allergy inmunotherapy unit in Madrid, Spain

Safety in the peach juice food challenge in LTP allergic patients

Safety of 300IR liquid sublingual immunotherapy of cat allergen extract for respiratory allergy to cat dander: a post-marketing experience

Safety of Avapritinib in Indolent Systemic Mastocytosis (ISM): Longer Term Follow-up From the PIONEER Study

Safety of Hymenoptera Venom Immunotherapy in Patients with Oncological and Autoimmune Diseases: A Clinical Case Series

Safety of Remibrutinib in Patients With Chronic Spontaneous Urticaria: Results From the Phase 3 REMIX-1 and REMIX-2 Studies

Safety of Single-Dose Drug Provocation Test in Low Risk Non-Immediate Reactions with Beta-Lactam Antibiotics in Children

Safety of Skin Prick Tests: more than 30 years of spontaneous data from real practice

Safety of a Three-Step Provocation Test in Mild Hypersensitivity Reactions to Beta-Lactams

Safety of a cluster strategy, effectiveness and immunological changes in allergic children sensitized to house dust mites with native and modified subcutaneous immunotherapy treatment

Safety of allergen immunotherapy in patients with severe asthma. A real-world, multicentre, observational retrospective study

Safety of cefixime use in penicillin allergic pediatric patients – a review spanning from 2010 to 2023 at a tertiary hospital

Safety of direct and single-dose drug provocation test in low-risk penicillin allergy labels

Safety of dupilumab in patients with severe asthma: real-life experience

Safety of lanadelumab in an immunosuppressed kidney transplant patient with high cardiovascular risk – a case report

Safety of oral immunotherapy in preschool aged children with single and multiple food allergy (the ORKA trial): a prospective intervention study

Safety of subcutaneous immunotherapy with mixtures of two allergens at maximum concentration: 10 year real-world data

Safety of the SQ HDM SLIT-tablet in children (5–11 years) with house dust mite allergic rhinitis/rhinoconjunctivitis in the MT-12 phase III trial

Safety of ultra-rush immunotherapy starting protocol with the molecular extract Diater Alt a 1 mol mix

Safety profile in clinical trials of sublingual immunotherapy with carbamylated monomeric allergoid

Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics of IGNX001 in Peanut-Allergic (PA) Adults and Older Adolescents – Day 8 Safety Data for Cohort 1 of the ACCELERATE Peanut Study

Study design for the saFety assessment of an Accelerated up-dosing scheme using one Strength of a native house dust mite allergen extract for subcutaneous immunoTherapy in children with allergic asthma in China (FAST II study)

Subcutaneous allergen-specific immunotherapy- Safety and risk factors of adverse effects. Data from a tertiary allergy centre

Supporting second victims: linkages between patient safety and well-being of healthcare workers in allergy departments

The Efficacy and Safety of Stepwise Oral Food Challenge in Children with Hen’s Egg Allergy

The Efficacy and Safety of Ultra-Rush Subcutaneous Immunotherapy for Allergic Rhinitis

The Safety and Effectiveness of Using the 6-Step iMAP Milk Ladder in Children with IgE-Mediated Cow’s Milk Protein Allergy

The effectiveness and safety of Abrocitinib treatment for severe atopic dermatitis in the real-world data in Turkey

The safety of an optimal accelerated immunotherapy for allergic rhinitis in adolescent and adult patients in China (PERFECT study)

Therapeutic effectiveness and safety of cannabinoids in the treatment of atopic dermatitis: a systematic review

Treatment with the 300 IR house dust mite sublingual tablet is safe and well tolerated in adults and adolescents in a real-world data setting – results of a non-interventional post authorization safety study

Use and safety of canakinumab during pregnancy

Venom Immunotherapy in children and adolescents: safety and outcome in a study group from a third level Italian center

Welcome

Only match titles

What are you looking for?

Knowledge Hub

Website

Only match titles

What are you looking for?

Knowledge Hub

Courses

Webinars

Event Resources

Sponsored Symposia

Website

Sessions

Annual Congress